PPARG and systemic lupus erythematosus: They belong to the family of drugs that activate the peroxisome proliferator-activated receptor-γ (PPAR-γ) and have been found to confer antiatherogenic and anti-inflammatory effects in diabetics and non-diabetic patient groups.18 In animal models of lupus, TZDs improved vascular damage, endothelial dysfunction and disease activity.19–21 Furthermore, PGZ improved vascular function and disease activity in rheumatoid arthritis.22 23